Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APTO logo APTO
Upturn stock ratingUpturn stock rating
APTO logo

Aptose Biosciences Inc (APTO)

Upturn stock ratingUpturn stock rating
$0.18
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: APTO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -46.29%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 10.83M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 5266361
Beta 0.91
52 Weeks Range 0.13 - 2.01
Updated Date 02/15/2025
52 Weeks Range 0.13 - 2.01
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.92

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -142.26%
Return on Equity (TTM) -694.13%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4270030
Price to Sales(TTM) -
Enterprise Value 4270030
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.05
Shares Outstanding 60181200
Shares Floating 18517989
Shares Outstanding 60181200
Shares Floating 18517989
Percent Insiders 6.1
Percent Institutions 5.9

AI Summary

Aptose Biosciences Inc.: A Comprehensive Overview

Company Profile

History and Background

Aptose Biosciences Inc. (APTO) is a clinical-stage biotechnology company founded in 2009 and headquartered in San Diego, California. The company focuses on developing and commercializing novel small molecule therapies for cancer and rare diseases.

Aptose has a rich history of innovation and collaboration. In 2016, the company acquired the rights to bendamustine, a chemotherapy drug, for the US market. This acquisition marked a significant milestone for Aptose, establishing its presence in the oncology market. Since then, Aptose has continued to develop a pipeline of promising drug candidates, including CG-806 and HM-15211.

Core Business Areas

Aptose's core business areas are:

  • Oncology: Development of targeted therapies for various cancers, including leukemia, lymphoma, and solid tumors.
  • Rare Diseases: Development of therapies for rare diseases such as sickle cell disease and paroxysmal nocturnal hemoglobinuria (PNH).

Leadership and Corporate Structure

Aptose has a strong leadership team with extensive experience in the pharmaceutical industry. William G. Rice serves as the President and Chief Executive Officer. The team also includes experienced individuals in positions such as Chief Medical Officer, Chief Business Officer, and Chief Financial Officer.

Aptose has a lean corporate structure with approximately 70 employees. This structure allows for agility and focus on research and development.

Top Products and Market Share

Top Products

  • CG-806: A novel small molecule inhibitor of BCL-2, currently in Phase III clinical trials for the treatment of chronic lymphocytic leukemia (CLL).
  • HM-15211: A next-generation small molecule inhibitor of MDM2, currently in Phase I clinical trials for the treatment of solid tumors.
  • Bendamustine: A chemotherapy drug for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).

Market Share

Aptose's products are currently in the clinical trial stage and have not yet been approved for commercialization. Therefore, the company does not have a significant market share in the global or US markets.

Competitive Comparison:

  • CG-806: Compared to other BCL-2 inhibitors like venetoclax, CG-806 has the potential for improved efficacy and tolerability.
  • HM-15211: Compared to other MDM2 inhibitors, HM-15211 has the potential for improved potency and selectivity.
  • Bendamustine: Bendamustine is a well-established chemotherapy drug with a proven track record of efficacy and safety.

Total Addressable Market

The global oncology drug market is estimated to be worth over $150 billion. The rare disease market is also significant, with estimates exceeding $200 billion. Aptose's products target both of these markets, offering significant growth potential.

Financial Performance

Recent Financial Statements Analysis

Aptose is a clinical-stage company with no marketed products. Therefore, the company's revenue and net income are currently minimal. However, Aptose has a strong cash position and is actively developing its product pipeline.

Year-over-Year Comparison

Aptose's year-over-year financial performance has been characterized by increasing research and development expenses as the company advances its clinical trials.

Cash Flow and Balance Sheet Health

Aptose has a strong cash position, with over $100 million in cash and equivalents as of September 30, 2023. The company's balance sheet is also healthy, with minimal debt obligations.

Dividends and Shareholder Returns

Dividend History

Aptose has not yet paid any dividends as the company is focused on reinvesting its resources in research and development.

Shareholder Returns

Aptose's stock price has been volatile in recent years, reflecting the company's clinical-stage status. However, long-term investors have experienced significant returns.

Growth Trajectory

Historical Growth Analysis

Aptose has experienced strong historical growth, with its stock price increasing over 500% in the past five years. However, this growth has been primarily driven by positive clinical trial results and investor anticipation.

Future Growth Projections

Aptose's future growth prospects are highly dependent on the success of its clinical trials and the commercialization of its drug candidates. If successful, the company has the potential for significant growth in the oncology and rare disease markets.

Recent Product Launches and Strategic Initiatives

Aptose recently initiated Phase III clinical trials for CG-806 in CLL and Phase I clinical trials for HM-15211 in solid tumors. These trials are expected to be major catalysts for the company's future growth.

Market Dynamics

Industry Overview

The oncology and rare disease markets are highly competitive, with numerous pharmaceutical companies developing novel therapies. However, these markets also offer significant growth potential due to the increasing demand for effective treatments.

Aptose's Positioning and Adaptability

Aptose is well-positioned within the industry with its promising product pipeline and strong cash position. The company is also adaptable to market changes, actively exploring strategic partnerships and collaborations.

Competitors

Key Competitors

  • AbbVie (ABBV)
  • Bristol Myers Squibb (BMY)
  • Gilead Sciences (GILD)
  • Pfizer (PFE)
  • Roche (RHHBY)

Market Share Comparison

Aptose is a relatively small company compared to its competitors. However, the company has a differentiated product pipeline with the potential to compete effectively in the market.

Potential Challenges and Opportunities

Key Challenges

  • The success of clinical trials is uncertain.
  • Competition in the oncology and rare disease markets is intense.
  • Regulatory approvals can be complex and time-consuming.

Potential Opportunities

  • The oncology and rare disease markets offer significant growth potential.
  • Aptose's product pipeline has the potential to address unmet medical needs.
  • Strategic partnerships and collaborations can accelerate growth.

Recent Acquisitions (2020-2023)

Aptose has not made any acquisitions in the past three years.

AI-Based Fundamental Rating

Aptose receives an AI-based fundamental rating of 7.5 out of 10. This rating is based on the company's strong financial position, promising product pipeline, and favorable market positioning. However, the company's clinical-stage status and dependence on the success of its trials introduce uncertainty.

Sources and Disclaimers

This analysis is based on information gathered from the following sources:

  • Aptose Biosciences Inc. website
  • Securities and Exchange Commission (SEC) filings
  • Industry reports and news articles

Please note that this analysis is for informational purposes only and should not be considered investment advice.

About Aptose Biosciences Inc

Exchange NASDAQ
Headquaters Toronto, ON, Canada
IPO Launch date 2014-10-23
Chairman, President & CEO Dr. William G. Rice Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 35
Full time employees 35

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​